Tag: uterine fibroid embolization device market growth

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Uterine Fibroid Embolization Device Market Size, Value And Growth Trajectory Through 2030

The uterine fibroid embolization device market size has demonstrated consistent growth in recent years. It is projected to expand from $5.93 billion in 2025 to $6.19 billion in 2026, recording a compound annual growth rate (CAGR) of 4.4%. This historical growth can be linked to several factors, including the increasing prevalence of uterine fibroids among women of reproductive age, a rising number of gynecological procedures performed in hospital and clinic settings, the growing adoption of uterine artery embolization in interventional radiology, greater awareness of alternatives to open surgical myomectomy, and the expansion of minimally invasive treatment workflows within tertiary care centers.

The uterine fibroid embolization device market size is anticipated to demonstrate consistent growth in the coming years, reaching $7.33 billion in 2030 at a compound annual growth rate (CAGR) of 4.3%. This expansion over the forecast period is propelled by factors such as increasing demand for uterus-sparing fibroid treatments among younger patient groups, a rising clinical inclination toward minimally invasive and non-invasive treatment methods, enhanced procedural adoption in ambulatory surgical centers, the wider application of ablation and embolization devices for reducing fibroid size, and increased investments in advanced delivery catheters and embolic systems to improve treatment precision. Significant trends during this period involve the increasing adoption of minimally invasive embolization techniques for uterine fibroid management, a growing clinical preference for organ-preserving alternatives to hysterectomy, the expanded utilization of image-guided interventional devices for targeted fibroid therapy, the broader use of embolization procedures in outpatient and ambulatory surgical settings, and an escalating demand for precision delivery systems to enhance procedural safety and outcomes.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=25111898&type=smp&name=Uterine%20Fibroid%20Embolization%20Device%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Uterine Fibroid Embolization Device Market Industry Drivers: What’s Behind The Revenue Growth?

The increasing need for minimally invasive surgeries is projected to drive expansion within the uterine fibroid embolization device market in the future. These surgical techniques involve small cuts or natural bodily entry points to reach and treat internal body parts, reducing patient trauma. The preference for minimally invasive procedures is rising among both patients and medical professionals due to their benefits in accelerating recovery, reducing complications, and enhancing comfort. Uterine fibroid embolization devices play a crucial role in these procedures by allowing for accurate and successful fibroid treatment, thereby bettering patient results and procedural effectiveness. For example, AOS Open, a US-based medical journal, reported that in January 2025, the percentage of minimally invasive surgeries performed in hospitals utilizing robotic-assisted systems climbed to 65.8% in 2025, an increase from 60.5% in 2022. Consequently, the escalating demand for minimally invasive surgeries is a key factor propelling the expansion of the uterine fibroid embolization device market.

Uterine Fibroid Embolization Device Market Segmentation: How Does The Market Break Down By Category?

The uterine fibroid embolization device market covered in this report is segmented –

1) By Technology: Surgical Techniques, Laparoscopic Techniques, Ablation Techniques, Embolization Techniques

2) By Mode Of Treatment: Invasive Treatment, Minimally Invasive Treatment

3) By End User: Hospitals, Clinics, Ambulatory Surgical Center

Subsegments:

1) By Surgical Techniques: Open Surgery, Myomectomy

2) By Laparoscopic Techniques: Laparoscopic Myomectomy, Laparoscopic Hysterectomy

3) By Ablation Techniques: Radiofrequency Ablation, Microwave Ablation, Cryoablation

4) By Embolization Techniques: Transcatheter Arterial Embolization (TAE), Uterine Artery Embolization (UAE)

#Uterine Fibroid Embolization Device Market Growth Trends: What’s Shaping The Future Outlook?

Leading companies within the uterine fibroid embolization device market are innovating with products such as Minimally invasive fibroid management software, aimed at improving the precision and efficiency of uterine fibroid treatment. Minimally invasive fibroid management software represents an advanced digital platform designed to assist clinicians in the planning, guidance, and execution of minimally invasive procedures for uterine fibroids, thereby enhancing procedural accuracy, safety, and overall patient results. For example, in September 2024, Gynesonics, a US–based medical device firm specializing in minimally invasive gynecologic treatments, introduced its SMART OS 2.4 software for the Sonata System to improve the management of uterine fibroids. SMART OS 2.4 refines the proprietary SMART Guide by reducing the minimum ablation zone size from 2.0 × 1.3 cm to 1.6 × 1.2 cm, cutting ablation volume by 38%, and optimizing the Thermal Safety Border for smaller fibroids. These advancements enable more precise, controlled treatments while protecting healthy uterine tissue, thereby boosting both procedural efficiency and patient outcomes.

Uterine Fibroid Embolization Device Market Competitive Landscape: Which Companies Lead The Industry?

Major companies operating in the uterine fibroid embolization device market are Johnson and Johnson Pvt Ltd., Medtronic plc., Boston Scientific Corporation, Olympus Corporation, Terumo Corporation, Ethicon Inc., Hologic Inc., CooperSurgical Inc., Cook Medical Inc., Karl Storz GmbH, Merit Medical Systems, CONMED Corporation, Lumenis Ltd., Richard Wolf GmbH, BTG International Ltd., Healthium MedTech Pvt. Ltd., Hironic Co.Ltd, Minerva Surgical Inc., Gynesonics Inc., Advanced Surgical Concepts PLLC

View The Full Uterine Fibroid Embolization Device Market Report:

https://thebusinessresearchcompany.com/report/uterine-fibroid-embolization-device-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Uterine Fibroid Embolization Device Market Regional Outlook: Where Is Opportunity Concentrated?

North America was the largest region in the uterine fibroid embolization device market in 2025. The regions covered in the uterine fibroid embolization device market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Are The Market Size Estimates For The Uterine Fibroid Embolization Device Market In 2026 And 2030?

The market size for uterine fibroid embolization devices has experienced consistent growth over recent years. This market is projected to expand from $5.93 billion in 2025 to $6.19 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 4.4%. Historically, this expansion has been driven by several factors, including the increasing occurrence of uterine fibroids in women of reproductive age, a rise in gynecological procedures performed in hospitals and clinics, the enhanced adoption of uterine artery embolization within interventional radiology, greater knowledge of treatments that offer alternatives to open surgical myomectomy, and the broader implementation of minimally invasive treatment protocols in tertiary care facilities.

The market for uterine fibroid embolization devices is anticipated to experience consistent expansion over the upcoming years. This market is projected to reach $7.33 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.3%. The anticipated growth during this period stems from several factors, including an increased need for uterus-sparing fibroid solutions, particularly among younger patients, a growing medical preference for non-invasive and minimally invasive treatments, greater implementation of procedures in ambulatory surgical centers, the expanded application of ablation and embolization devices for reducing fibroid dimensions, and heightened investments in sophisticated delivery catheters and embolic systems aimed at enhancing treatment accuracy. Key developments expected in the forecast period encompass a surge in the adoption of minimally invasive embolization methods for addressing uterine fibroids, a rising clinical inclination towards alternatives to hysterectomy that preserve organs, increased deployment of image-guided interventional devices for precise fibroid therapy, the broadening application of embolization procedures in outpatient and ambulatory settings, and an escalating requirement for accurate delivery systems to boost procedural safety and effectiveness.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/uterine-fibroid-embolization-device-global-market-report

Which Strong Drivers Are Impacting The Uterine Fibroid Embolization Device Market Growth?

The increasing demand for minimally invasive surgeries is anticipated to propel the expansion of the uterine fibroid embolization device market moving forward. Minimally invasive surgeries represent surgical approaches that utilize small incisions or natural bodily openings to reach and address internal structures, organs, or tissues, thereby minimizing patient trauma. The appetite for minimally invasive procedures is on the rise as more patients and healthcare providers favor treatments that reduce recuperation time, lower potential complication risks, and improve general comfort. Uterine fibroid embolization devices support these procedures by facilitating precise and effective treatment of fibroids, which in turn enhances patient outcomes and procedural efficiency. For instance, in January 2025, according to AOS Open, a US-based medical journal, the prevalence of minimally invasive surgeries in hospitals equipped with robotic-assisted systems increased to 65.8% in 2025, marking a rise from 60.5% in 2022. Consequently, the growing demand for minimally invasive surgeries is a primary driver for the growth of the uterine fibroid embolization device market.

Which Segment Classifications Are Used In The Uterine Fibroid Embolization Device Market Segment Analysis?

The uterine fibroid embolization device market covered in this report is segmented –

1) By Technology: Surgical Techniques, Laparoscopic Techniques, Ablation Techniques, Embolization Techniques

2) By Mode Of Treatment: Invasive Treatment, Minimally Invasive Treatment

3) By End User: Hospitals, Clinics, Ambulatory Surgical Center

Subsegments:

1) By Surgical Techniques: Open Surgery, Myomectomy

2) By Laparoscopic Techniques: Laparoscopic Myomectomy, Laparoscopic Hysterectomy

3) By Ablation Techniques: Radiofrequency Ablation, Microwave Ablation, Cryoablation

4) By Embolization Techniques: Transcatheter Arterial Embolization (TAE), Uterine Artery Embolization (UAE)

Which Trends Are Contributing To Changes In The Uterine Fibroid Embolization Device Market?

Leading companies within the uterine fibroid embolization device market are developing innovative products, such as Minimally invasive fibroid management software, to enhance the precision and efficiency of uterine fibroid treatment. This Minimally invasive fibroid management software represents an advanced digital platform designed to assist clinicians in the planning, guidance, and execution of minimally invasive procedures for treating uterine fibroids, thereby improving procedural precision, safety, and overall patient outcomes. For instance, in September 2024, Gynesonics, a US-based medical device company specializing in minimally invasive gynecologic treatments, launched SMART OS 2.4 software for the Sonata System to enhance the management of uterine fibroids. SMART OS 2.4 improves the proprietary SMART Guide by reducing the minimum ablation zone size from 2.0 × 1.3 cm to 1.6 × 1.2 cm, decreasing ablation volume by 38%, and optimizing the Thermal Safety Border for smaller fibroids. These enhancements allow for more precise, controlled treatments while preserving healthy uterine tissue, improving both procedural efficiency and patient outcomes.

Which Firms Are Contributing To The Uterine Fibroid Embolization Device Market Ecosystem?

Major companies operating in the uterine fibroid embolization device market are Johnson and Johnson Pvt Ltd., Medtronic plc., Boston Scientific Corporation, Olympus Corporation, Terumo Corporation, Ethicon Inc., Hologic Inc., CooperSurgical Inc., Cook Medical Inc., Karl Storz GmbH, Merit Medical Systems, CONMED Corporation, Lumenis Ltd., Richard Wolf GmbH, BTG International Ltd., Healthium MedTech Pvt. Ltd., Hironic Co.Ltd, Minerva Surgical Inc., Gynesonics Inc., Advanced Surgical Concepts PLLC

Get The Full Uterine Fibroid Embolization Device Market Report:

https://www.thebusinessresearchcompany.com/report/uterine-fibroid-embolization-device-global-market-report

Which Region Is The Largest In The Uterine Fibroid Embolization Device Market?

North America was the largest region in the uterine fibroid embolization device market in 2025. The regions covered in the uterine fibroid embolization device market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Uterine Fibroid Embolization Device Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/uterine-fibroid-embolization-device-global-market-report

Browse Through More Reports Similar to the Global Uterine Fibroid Embolization Device Market 2026, By The Business Research Company

Uterine Fibroids Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/uterine-fibroids-treatment-global-market-report

Uterine Fibroids Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/uterine-fibroids-treatment-global-market-report

Tumor Embolization Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/tumor-embolization-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Anticipated For The Uterine Fibroid Embolization Device Market Over The Period 2026–2030?

The market for uterine fibroid embolization devices has observed consistent growth recently. It is forecast to increase from $5.93 billion in 2025 to $6.19 billion in 2026, progressing at a compound annual growth rate (CAGR) of 4.4%. The expansion witnessed in prior periods can be attributed to the rising occurrence of uterine fibroids in women of reproductive age, an increasing volume of gynecological procedures conducted in hospitals and clinics, the growing utilization of uterine artery embolization in interventional radiology, improved public understanding of alternatives to open surgical myomectomy, and the expansion of minimally invasive treatment approaches in specialized medical centers.

The uterine fibroid embolization device market size is anticipated to experience consistent expansion over the upcoming years. It is projected to reach $7.33 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 4.3%. This growth during the forecast period can be ascribed to several factors, including an escalating demand for uterus-sparing fibroid therapies among younger patients, an expanding clinical preference for minimally invasive and non-invasive treatment approaches, a surge in procedural adoption within ambulatory surgical centers, the broadened application of ablation and embolization devices to reduce fibroid size, and increased investments in sophisticated delivery catheters and embolic systems to enhance treatment accuracy. Key trends during this period encompass the increasing embrace of minimally invasive embolization methods for addressing uterine fibroids, a growing clinical leaning towards organ-preserving options instead of hysterectomy, the greater deployment of image-guided interventional devices for focused fibroid treatment, the wider application of embolization procedures in outpatient and ambulatory surgical environments, and an escalating need for precise delivery systems to enhance safety and results of procedures.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13551&type=smp

Which Economic Or Industry Drivers Are Impacting The Uterine Fibroid Embolization Device Market?

The increasing requirement for minimally invasive surgical procedures is anticipated to fuel the expansion of the uterine fibroid embolization device market in the future. These surgeries involve surgical techniques that utilize small cuts or existing body orifices to reach and manage internal structures, organs, or tissues, thereby reducing patient trauma. The preference for minimally invasive procedures is rising because both patients and medical professionals favor interventions that shorten recovery periods, diminish the likelihood of complications, and enhance general well-being. Uterine fibroid embolization devices facilitate such procedures by providing accurate and potent treatment for fibroids, leading to better patient results and greater procedural effectiveness. As an illustration, in January 2025, data from AOS Open, a US-based medical journal, indicated that the proportion of minimally invasive surgeries performed in hospitals equipped with robotic-assisted systems increased to 65.8% in 2025, marking an ascent from 60.5% in 2022. Consequently, the expanding need for minimally invasive surgeries is a key factor propelling the development of the uterine fibroid embolization device market.

How Is The Uterine Fibroid Embolization Device Market Divided Into Its Major Segments?

The uterine fibroid embolization device market covered in this report is segmented –

1) By Technology: Surgical Techniques, Laparoscopic Techniques, Ablation Techniques, Embolization Techniques

2) By Mode Of Treatment: Invasive Treatment, Minimally Invasive Treatment

3) By End User: Hospitals, Clinics, Ambulatory Surgical Center

Subsegments:

1) By Surgical Techniques: Open Surgery, Myomectomy

2) By Laparoscopic Techniques: Laparoscopic Myomectomy, Laparoscopic Hysterectomy

3) By Ablation Techniques: Radiofrequency Ablation, Microwave Ablation, Cryoablation

4) By Embolization Techniques: Transcatheter Arterial Embolization (TAE), Uterine Artery Embolization (UAE)

How Are Trends Transforming The Uterine Fibroid Embolization Device Market Landscape?

Leading companies in the uterine fibroid embolization device market are creating advanced products, such as Minimally invasive fibroid management software, to boost the accuracy and effectiveness of uterine fibroid treatment. This software is an advanced digital platform designed to assist clinicians in the planning, guidance, and execution of minimally invasive procedures for uterine fibroids, thereby enhancing procedural precision, safety, and overall patient outcomes. For example, in September 2024, Gynesonics, a US–based medical device company specializing in minimally invasive gynecologic treatments, introduced SMART OS 2.4 software for its Sonata System to better manage uterine fibroids. SMART OS 2.4 enhances the proprietary SMART Guide by reducing the smallest ablation zone size from 2.0 × 1.3 cm to 1.6 × 1.2 cm, lowering ablation volume by 38%, and refining the Thermal Safety Border for smaller fibroids. These improvements enable more accurate, controlled treatments while preserving healthy uterine tissue, which enhances both procedural efficiency and patient outcomes.

Who Are The Prominent Organizations Shaping The Uterine Fibroid Embolization Device Market?

Major companies operating in the uterine fibroid embolization device market are Johnson and Johnson Pvt Ltd., Medtronic plc., Boston Scientific Corporation, Olympus Corporation, Terumo Corporation, Ethicon Inc., Hologic Inc., CooperSurgical Inc., Cook Medical Inc., Karl Storz GmbH, Merit Medical Systems, CONMED Corporation, Lumenis Ltd., Richard Wolf GmbH, BTG International Ltd., Healthium MedTech Pvt. Ltd., Hironic Co.Ltd, Minerva Surgical Inc., Gynesonics Inc., Advanced Surgical Concepts PLLC

Read the full uterine fibroid embolization device market report here:

https://www.thebusinessresearchcompany.com/report/uterine-fibroid-embolization-device-global-market-report

What Are The Top-Performing Regions Within The Uterine Fibroid Embolization Device Market?

North America was the largest region in the uterine fibroid embolization device market in 2025. The regions covered in the uterine fibroid embolization device market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Uterine Fibroid Embolization Device Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13551&type=smp

Browse Through More Reports Similar to the Global Uterine Fibroid Embolization Device Market 2026, By The Business Research Company

Uterine Fibroids Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/uterine-fibroids-treatment-global-market-report

Uterine Fibroids Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/uterine-fibroids-treatment-global-market-report

Tumor Embolization Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/tumor-embolization-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the workstation graphics processing unit (gpu) market from 2026–2035 with trusted insights from The Business Research Company

What upper market value could the Uterine Fibroid Embolization Device Market reach by 2030 starting from 2026 levels?

The uterine fibroid embolization device market has experienced consistent expansion over recent years. This market is projected to grow from $5.93 billion in 2025 to $6.19 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 4.4%. The historical growth can be linked to factors such as the increasing prevalence of uterine fibroids among women of reproductive age, a rising number of gynecological procedures performed in hospital and clinic settings, the growing adoption of uterine artery embolization in interventional radiology, enhanced awareness of alternatives to open surgical myomectomy, and the broader implementation of minimally invasive treatment workflows in tertiary care centers.

The uterine fibroid embolization device market is anticipated to experience consistent expansion over the upcoming years. This market is projected to reach $7.33 billion in 2030, with a compound annual growth rate (CAGR) of 4.3%. The increase during the forecast period can be linked to several factors, including a heightened demand for uterus-sparing fibroid therapies among younger patients, a growing medical preference for less invasive and non-invasive treatment approaches, increased procedural adoption in ambulatory surgical centers, the expanded application of ablation and embolization devices for reducing fibroid size, and increased capital directed towards advanced delivery catheters and embolic systems to enhance treatment accuracy. Key trends anticipated in the same period involve the increasing embrace of minimally invasive embolization methods for uterine fibroid management, a stronger clinical inclination towards organ-preserving options instead of hysterectomy, greater deployment of image-guided interventional devices for targeted fibroid treatment, the broadened application of embolization procedures in outpatient and ambulatory surgical environments, and a rising need for precision delivery systems to enhance procedural safety and patient outcomes.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13551&type=smp

Which Drivers Are Influencing Long-Term Growth In The Uterine Fibroid Embolization Device Market?

The escalating need for minimally invasive surgical procedures is anticipated to fuel the expansion of the uterine fibroid embolization device market. Minimally invasive surgeries are surgical techniques that employ small incisions or the body’s natural openings to access and treat internal structures, organs, or tissues, thereby minimizing patient trauma. The preference for minimally invasive procedures is growing as both patients and healthcare providers seek treatments that reduce recovery times, lower complication risks, and enhance overall comfort. Uterine fibroid embolization devices are instrumental in these procedures, enabling precise and effective treatment of fibroids, which improves patient outcomes and procedural efficiency. For instance, in January 2025, according to AOS Open, a US-based medical journal, the rate of minimally invasive surgeries in hospitals with robotic-assisted systems has risen to 65.8% in 2025, up from 60.5% in 2022. Thus, the increasing demand for minimally invasive surgeries is a primary driver for the growth of the uterine fibroid embolization device market.

Which Segments Are Driving Activity In The Uterine Fibroid Embolization Device Market?

The uterine fibroid embolization device market covered in this report is segmented –

1) By Technology: Surgical Techniques, Laparoscopic Techniques, Ablation Techniques, Embolization Techniques

2) By Mode Of Treatment: Invasive Treatment, Minimally Invasive Treatment

3) By End User: Hospitals, Clinics, Ambulatory Surgical Center

Subsegments:

1) By Surgical Techniques: Open Surgery, Myomectomy

2) By Laparoscopic Techniques: Laparoscopic Myomectomy, Laparoscopic Hysterectomy

3) By Ablation Techniques: Radiofrequency Ablation, Microwave Ablation, Cryoablation

4) By Embolization Techniques: Transcatheter Arterial Embolization (TAE), Uterine Artery Embolization (UAE)

Which Trends Are Influencing The Performance And Direction Of The Uterine Fibroid Embolization Device Market?

Leading companies in the uterine fibroid embolization device market are developing innovative offerings, such as Minimally invasive fibroid management software, to improve the precision and efficiency of uterine fibroid treatment. Minimally invasive fibroid management software denotes a sophisticated digital platform created to assist clinicians with the planning, guidance, and execution of minimally invasive procedures for uterine fibroids, thereby enhancing procedural accuracy, safety, and overall patient results. For instance, in September 2024, Gynesonics, a US-based medical device company focused on minimally invasive gynecologic treatments, released SMART OS 2.4 software for its Sonata System to better manage uterine fibroids. SMART OS 2.4 upgrades the proprietary SMART Guide by reducing the minimum ablation zone size from 2.0 × 1.3 cm to 1.6 × 1.2 cm, cutting ablation volume by 38%, and optimizing the Thermal Safety Border for smaller fibroids. These advancements facilitate more precise, controlled treatments while protecting healthy uterine tissue, consequently improving both procedural efficiency and patient outcomes.

Which Major Firms Are Strengthening Their Position In The Uterine Fibroid Embolization Device Market?

Major companies operating in the uterine fibroid embolization device market are Johnson and Johnson Pvt Ltd., Medtronic plc., Boston Scientific Corporation, Olympus Corporation, Terumo Corporation, Ethicon Inc., Hologic Inc., CooperSurgical Inc., Cook Medical Inc., Karl Storz GmbH, Merit Medical Systems, CONMED Corporation, Lumenis Ltd., Richard Wolf GmbH, BTG International Ltd., Healthium MedTech Pvt. Ltd., Hironic Co.Ltd, Minerva Surgical Inc., Gynesonics Inc., Advanced Surgical Concepts PLLC

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/uterine-fibroid-embolization-device-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Uterine Fibroid Embolization Device Market?

North America was the largest region in the uterine fibroid embolization device market in 2025. The regions covered in the uterine fibroid embolization device market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Uterine Fibroid Embolization Device Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13551&type=smp

Browse Through More Reports Similar to the Global Uterine Fibroid Embolization Device Market 2026, By The Business Research Company

Uterine Fibroids Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/uterine-fibroids-treatment-global-market-report

Uterine Fibroids Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/uterine-fibroids-treatment-global-market-report

Tumor Embolization Devices Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/tumor-embolization-devices-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Uncover key drivers, emerging technologies, and competitive movements shaping the uterine fibroid embolization device market from 2025–2034 with trusted insights from The Business Research Company

How Much Will The Uterine Fibroid Embolization Device Market Be Worth By 2029, And What CAGR Will It Achieve?

The uterine fibroid embolization device market size has demonstrated consistent expansion in recent years. Its growth is projected from $5.62 billion in 2024 to $5.89 billion by 2025, achieving a compound annual growth rate (CAGR) of 4.7%. The market’s historical development can be attributed to the rising incidence of uterine fibroids, a growing preference for non-surgical alternatives, various awareness and education initiatives, a sharpened focus on women’s health, the ongoing shift towards outpatient procedures, and robust physician training programs.

The uterine fibroid embolization device market is projected to experience consistent expansion over the upcoming years. This market is set to reach a valuation of $6.96 billion by 2029, expanding at a compound annual growth rate (CAGR) of 4.3%. This anticipated growth during the forecast period is attributable to several factors, including heightened awareness of non-invasive therapies, the worldwide extension of healthcare provisions, a surge in women’s health programs, the incorporation of multidisciplinary care models, and an increase in outpatient service offerings. Key trends anticipated during this period encompass a rising embrace of minimally invasive interventions, continuous improvements in embolic agents, tailored treatment methodologies, an emphasis on outpatient UFE procedures, the incorporation of advanced imaging technologies, and ongoing research into bioresorbable embolic agents.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13551&type=smp

Which Factors Are Driving The Uterine Fibroid Embolization Device Market Forward?

The increasing demand for minimally invasive surgeries is anticipated to fuel the expansion of the uterine fibroid embolization device market. Minimally invasive surgeries are defined as surgical methods employing small incisions or natural bodily openings to access and treat internal structures, organs, or tissues, thereby minimizing patient trauma. Uterine fibroid embolization devices are crucial instruments that facilitate these less invasive procedures for effectively treating uterine fibroids. These specialized devices are carefully engineered to ensure minimal invasiveness through the use of small incisions, which lessens the impact on surrounding tissues. They directly address the growing preference for less invasive medical interventions, ultimately leading to improved patient outcomes. As an illustration, in August 2023, according to The Aesthetic Society, a US-based organization of plastic surgery and cosmetic medicine, Americans allocated over $11.8 billion to aesthetic procedures overall, marking a 2% increase from the preceding year. Consequently, the rising demand for minimally invasive surgeries is a key driver for the growth of the uterine fibroid embolization device market.

Which Segments Form The Key Structure Of The Uterine Fibroid Embolization Device Market?

The uterine fibroid embolization devicemarket covered in this report is segmented –

1) By Technology: Surgical Techniques, Laparoscopic Techniques, Ablation Techniques, Embolization Techniques

2) By Mode Of Treatment: Invasive Treatment, Minimally Invasive Treatment, Non-Invasive Treatment

3) By End User: Hospitals, Clinics, Ambulatory Surgical Center

Subsegments:

1) By Surgical Techniques: Open Surgery, Myomectomy

2) By Laparoscopic Techniques: Laparoscopic Myomectomy, Laparoscopic Hysterectomy

3) By Ablation Techniques: Radiofrequency Ablation, Microwave Ablation, Cryoablation

4) By Embolization Techniques: Transcatheter Arterial Embolization (TAE), Uterine Artery Embolization (UAE)

What Strategic Shifts And Innovations Are Influencing The Uterine Fibroid Embolization Device Market?

Leading companies in the uterine fibroid embolization device market are developing innovative products like the TruClear system to meet the increasing demand for minimally invasive uterine fibroid treatments and to enhance their safety and effectiveness. The TruClear system operates as a mechanical hysteroscopic tissue removal system, used for treating intrauterine abnormalities (IUA). It is a flexible catheter that is inserted into the uterus through the cervix. For example, in November 2022, Medtronic Private Limited, an India-based industrial medical equipment manufacturer, launched the new TruClear system. This mechanical hysteroscopic tissue removal system provides a safe and effective option for the treatment of intrauterine abnormalities (IUA). Additionally, it is a compact, adaptable catheter equipped with a spinning nitinol wire loop, continuous inflow and outflow capabilities, integrated suction, and high-definition imaging, all contributing to improved precision and safety in uterine fibroid treatment methods.

Which Firms Are Making The Biggest Impact In The Uterine Fibroid Embolization Device Market?

Major companies operating in the uterine fibroid embolization device market report are Johnson and Johnson Pvt Ltd., Abbott Laboratories, Medtronic plc., Siemens Healthineers Ltd., Koninklijke Philips N.V., Stryker Corporation, Boston Scientific Corporation, GE HealthCare Technologies Inc., Olympus Corporation, Terumo Corporation, Smith and Nephew plc., Ethicon Inc., Hologic Inc., CooperSurgical Inc., Ferring B.V., Cook Medical Inc., Karl Storz GmbH, Merit Medical Systems, CONMED Corporation, Amsino International Inc., Lumenis Ltd., Richard Wolf GmbH, BTG International Ltd., Healthium MedTech Pvt. Ltd., INSIGHTEC Ltd., Hironic Co.Ltd., Minerva Surgical Inc., Gynesonics Inc., Advanced Surgical Concepts PLLC, Hitachi Medical Corporation

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/uterine-fibroid-embolization-device-global-market-report

Which Region Is Expected To Lead The Uterine Fibroid Embolization Device Market In The Next Few Years?

North America was the largest region in the uterine fibroid embolization device market in 2024. The regions covered in the uterine fibroid embolization device market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=13551&type=smp

Browse Through More Reports Similar to the Global Uterine Fibroid Embolization Device Market 2025, By The Business Research Company

Immunochemistry Diagnostic Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/immunochemistry-diagnostic-devices-and-equipment-global-market-report

Implantable Drug Delivery Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/implantable-drug-delivery-devices-global-market-report

Interventional Cardiology Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/interventional-cardiology-devices-and-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Forecasted Market Size Estimates For The Uterine Fibroid Embolization Device Market Between 2025 And 2029?

The market for uterine fibroid embolization devices has experienced consistent expansion lately, projected to increase from $5.62 billion recorded in 2024 to $5.89 billion by 2025, achieving a compound annual growth rate (CAGR) of 4.7%. This expansion throughout the historical period is linked to several factors, including a rising frequency of uterine fibroids, a growing inclination toward treatments that avoid surgery, concerted efforts in awareness and education campaigns, heightened attention on overall women’s health, a trend favoring procedures conducted in outpatient settings, and the implementation of specialized physician training programs.

Projections indicate that the market encompassing devices for uterine fibroid embolization is poised for consistent expansion over the forthcoming period, reaching a valuation of $6.96 billion by 2029, driven by a compounded annual growth rate (CAGR) of 4.3%; this upward trajectory is fueled by heightened recognition of non-surgical therapeutic options, the worldwide broadening of medical care availability, a surge in programs dedicated to women’s health, the incorporation of care across multiple medical disciplines, and the proliferation of services offered in ambulatory settings.Key developments shaping this market during the forecast timeframe involve a greater uptake of procedures requiring minimal invasiveness, progress in the materials used as embolic agents, customized methods for patient care, concentrated efforts on performing UFE outside of hospital stays, the better assimilation of diagnostic imaging tools, and ongoing investigation into embolic agents that the body can naturally break down.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13551&type=smp

Which Drivers Are Impacting The Uterine Fibroid Embolization Device Market?

The increasing preference for surgical techniques characterized by minimal invasiveness is projected to be a key driver fueling the expansion of the market for uterine fibroid embolization devices. Such minimally invasive procedures involve accessing and addressing internal anatomy, organs, or tissues through either tiny cuts or the body’s natural orifices, the primary aim being to decrease bodily trauma for the patient. Devices utilized in uterine fibroid embolization are crucial instruments facilitating these less intrusive surgical methods for the successful treatment of uterine fibroids, as these specialized instruments are precision-engineered to maintain a low level of invasiveness by relying on small access points, thereby lessening damage to adjacent tissues while meeting the rising clinical need for procedures causing less disruption, which ultimately benefits patient recovery; as an illustration, data published in August 2023 by The Aesthetic Society, an American professional body focused on cosmetic and plastic surgery, indicated that expenditures on aesthetic treatments by Americans surpassed $11.8 billion in total, marking a 2 percent rise compared to the preceding year, thus underscoring how the rising appetite for less invasive surgical interventions directly propels the trajectory of the uterine fibroid embolization device sector.

How Is The Uterine Fibroid Embolization Device Market Classified Into Different Segments?

The uterine fibroid embolization devicemarket covered in this report is segmented –

1) By Technology: Surgical Techniques, Laparoscopic Techniques, Ablation Techniques, Embolization Techniques

2) By Mode Of Treatment: Invasive Treatment, Minimally Invasive Treatment, Non-Invasive Treatment

3) By End User: Hospitals, Clinics, Ambulatory Surgical Center

Subsegments:

1) By Surgical Techniques: Open Surgery, Myomectomy

2) By Laparoscopic Techniques: Laparoscopic Myomectomy, Laparoscopic Hysterectomy

3) By Ablation Techniques: Radiofrequency Ablation, Microwave Ablation, Cryoablation

4) By Embolization Techniques: Transcatheter Arterial Embolization (TAE), Uterine Artery Embolization (UAE)

What Trends Are Expected To Drive The Uterine Fibroid Embolization Device Market?

Leading corporations within the uterine fibroid embolization device sector are engaged in pioneering the creation of novel medical instruments, exemplified by the TruClear system, in response to the increasing demand for less invasive therapeutic approaches for uterine fibroids, aiming to simultaneously enhance both treatment safety and effectiveness. The TruClear apparatus functions as a mechanical hysteroscopic device designed specifically for excising intrauterine abnormalities (IUA), involving the introduction of a flexible catheter via the cervical pathway into the uterus. As an illustration, in November of 2022, Medtronic Private Limited, an established manufacturer of industrial medical hardware based in India, introduced this very TruClear system, which serves as an effective and secure method for managing IUA through mechanical hysteroscopic tissue extraction. Furthermore, this technology integrates several key features within its compact, pliable catheter design—namely, a rotating nitinol wire loop, continuous fluid circulation (both inflow and outflow), integrated vacuum functionality, and high-definition visual guidance—all of which collectively serve to boost the accuracy and security inherent in current uterine fibroid management modalities.

Who Are The Core Companies Influencing The Uterine Fibroid Embolization Device Market Landscape?

Major companies operating in the uterine fibroid embolization device market report are Johnson and Johnson Pvt Ltd., Abbott Laboratories, Medtronic plc., Siemens Healthineers Ltd., Koninklijke Philips N.V., Stryker Corporation, Boston Scientific Corporation, GE HealthCare Technologies Inc., Olympus Corporation, Terumo Corporation, Smith and Nephew plc., Ethicon Inc., Hologic Inc., CooperSurgical Inc., Ferring B.V., Cook Medical Inc., Karl Storz GmbH, Merit Medical Systems, CONMED Corporation, Amsino International Inc., Lumenis Ltd., Richard Wolf GmbH, BTG International Ltd., Healthium MedTech Pvt. Ltd., INSIGHTEC Ltd., Hironic Co.Ltd., Minerva Surgical Inc., Gynesonics Inc., Advanced Surgical Concepts PLLC, Hitachi Medical Corporation

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/uterine-fibroid-embolization-device-global-market-report

What Are The Key Regional Factors Influencing The Uterine Fibroid Embolization Device Market Growth?

North America was the largest region in the uterine fibroid embolization device market in 2024. The regions covered in the uterine fibroid embolization device market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Uterine Fibroid Embolization Device Market Report:

https://www.thebusinessresearchcompany.com/customise?id=13551&type=smp

Browse Through More Reports Similar to the Global Uterine Fibroid Embolization Device Market 2025, By The Business Research Company

Immunochemistry Diagnostic Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/immunochemistry-diagnostic-devices-and-equipment-global-market-report

Implantable Drug Delivery Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/implantable-drug-delivery-devices-global-market-report

Interventional Cardiology Devices And Equipment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/interventional-cardiology-devices-and-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

#What is the Projected CAGR for the Uterine Fibroid Embolization Device Market Size from 2025 to 2034?#_x000D_

In recent times, the market size of uterine fibroid embolization device has noticed consistent growth. The market, pegged at $5.62 billion in 2024, is expected to expand to $5.89 billion in 2025, recording a compound annual growth rate (CAGR) of 4.7%. Factors contributing to this growth during the historic period include rise in the count of uterine fibroid cases, inclination towards non-invasive alternate procedures, heightened awareness and educational drives, emphasis on women’s health, transition towards outpatient protocols, and physician instructional programs._x000D_

_x000D_

In the coming years, a consistent upswing is predicted for the uterine fibroid embolization device market, estimating a growth to $6.96 billion by 2029, with a 4.3% compound annual growth rate (CAGR). This projected growth during the forecast period is linked to the escalating consciousness of non-invasive treatments, global proliferation of healthcare services, an upward move in female health initiatives, consolidation with multidisciplinary care, and development of outpatient services. The forecast period also anticipates key trends such as the rise of minimally invasive procedures, progressive advancements in embolic agents, customized treatment protocols, emphasis on outpatient ufe procedures, incorporation of imaging technologies, and investigation into bioresorbable embolic agents._x000D_

_x000D_

#Download a free sample to assess the report’s scope and structure:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=13551&type=smp_x000D_

_x000D_

#What are the Fundamental Drivers and Innovations Shaping the Uterine Fibroid Embolization Device Market?#_x000D_

The uterine fibroid embolization device market is set to witness significant growth due to the increasing preference for minimally invasive surgeries. These surgeries, which involve small cuts or the usage of natural body openings for treating internal organs, tissues or structures, contribute to lesser body trauma for patients. Uterine fibroid embolization devices play a critical role in these surgeries as they allow for effective treatment of uterine fibroids. The thoughtful design of these devices allows small incisions and less impact on surrounding tissues, meeting the growing demand for less invasive medical procedures and resulting in better patient outcomes. As an example, The Aesthetic Society, a US-based organization specializing in plastic surgery and cosmetic medicine, reported in August 2023 that Americans spent over $11.8 billion on aesthetic procedures overall, indicating a 2% increase from the previous year. Hence, the rising demand for minimally invasive surgeries is a key factor bolstering the growth of the uterine fibroid embolization device market._x000D_

_x000D_

#How Is the Uterine Fibroid Embolization Device Market Segmented?#_x000D_

The uterine fibroid embolization devicemarket covered in this report is segmented – _x000D_

_x000D_

1) By Technology: Surgical Techniques, Laparoscopic Techniques, Ablation Techniques, Embolization Techniques_x000D_

2) By Mode Of Treatment: Invasive Treatment, Minimally Invasive Treatment, Non-Invasive Treatment_x000D_

3) By End User: Hospitals, Clinics, Ambulatory Surgical Center_x000D_

_x000D_

Subsegments:_x000D_

1) By Surgical Techniques: Open Surgery, Myomectomy_x000D_

2) By Laparoscopic Techniques: Laparoscopic Myomectomy, Laparoscopic Hysterectomy_x000D_

3) By Ablation Techniques: Radiofrequency Ablation, Microwave Ablation, Cryoablation_x000D_

4) By Embolization Techniques: Transcatheter Arterial Embolization (TAE), Uterine Artery Embolization (UAE)_x000D_

_x000D_

#Request customized data on this market:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=13551&type=smp_x000D_

_x000D_

#Which Regions Are Driving the Next Phase of the Uterine Fibroid Embolization Device Market Growth?#_x000D_

North America was the largest region in the uterine fibroid embolization device market in 2024. The regions covered in the uterine fibroid embolization device market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#What Key Trends Are Shaping the Future of the Uterine Fibroid Embolization Device Market?#_x000D_

Major corporations in the uterine fibroid embolization device market are innovating and launching products like the TruClear system to cater to the growing demand for less invasive uterine fibroids treatments and to enhance their safety and effectiveness. The TruClear device is a mechanical hysteroscopic tissue remover, utilized for addressing intrauterine abnormalities (IUA). With an adaptable catheter that is introduced into the uterus via the cervix, this system offers a significant therapeutic tool. Medtronic Private Limited, a medical equipment manufacturer based in India, for example, released the latest TruClear system in November 2022. This hysteroscopic tissue removal system provides a reliable and efficacious solution for IUA treatment. It attributes a compact, flexible catheter, spinning nitinol wire loop, constant inflow and outflow, built-in suction, and high-resolution imagery to increase the accuracy and safety of uterine fibroid treatment techniques._x000D_

_x000D_

#View the full report here:#_x000D_

https://www.thebusinessresearchcompany.com/report/uterine-fibroid-embolization-device-global-market-report_x000D_

_x000D_

#How Is the Uterine Fibroid Embolization Device Market Defined and What Are Its Core Parameters?#_x000D_

A uterine fibroid embolization device is a medical device that is used to treat noncancerous tumors using a minimally invasive process. Uterine fibroids are noncancerous growths of the uterus. This device restricts blood supply to uterine fibroids, causing them to shrink and eventually disappear._x000D_

_x000D_

#Purchase the full report and get a swift delivery:#_x000D_

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13551_x000D_

_x000D_

#About The Business Research Company:#_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Europe +44 7882 955267_x000D_

Asia & Others +44 7882 955267 & +91 8897263534_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Uterine Fibroid Embolization Device Market Growth in 2025?

The market size for uterine fibroid embolization devices has robustly expanded in recent years. The market is projected to grow from $5.62 billion in 2024 to $5.93 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 5.6%. This increasing growth in the past years can be credited to a rise in uterine fibroid cases, a preference for non-surgical treatments, initiatives for awareness and education, a concentration on women’s health, a shift towards outpatient services, and doctor training programs.

What Is the Forecast for the Uterine Fibroid Embolization Device Market Size Through 2029?

The market for uterine fibroid embolization devices is projected to steadily increase in the coming years, reaching $7.04 billion in 2029 with a CAGR of 4.4%. This growth during the forecast period can be accredited to heightened awareness about non-invasive treatment options, global expansion of healthcare services, increased focus on women’s health initiatives, integration of multidisciplinary care, and the broadening of outpatient care services. Key market trends for the forecast period encompass the rising adoption of minimally invasive surgeries, the advancement in embolic agents, personalized treatment strategies, emphasis on outpatient UFE procedures, the integration of imaging technologies, and research into bioresorbable embolic agents.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13551&type=smp

What are the Key Market Players in Uterine Fibroid Embolization Device Market and How They’re Evolving?

Major companies operating in the uterine fibroid embolization device market report are Johnson and Johnson Pvt Ltd., Abbott Laboratories, Medtronic plc., Siemens Healthineers Ltd., Koninklijke Philips N.V., Stryker Corporation, Boston Scientific Corporation, GE HealthCare Technologies Inc., Olympus Corporation, Terumo Corporation, Smith and Nephew plc., Ethicon Inc., Hologic Inc., CooperSurgical Inc., Ferring B.V., Cook Medical Inc., Karl Storz GmbH, Merit Medical Systems, CONMED Corporation, Amsino International Inc., Lumenis Ltd., Richard Wolf GmbH, BTG International Ltd., Healthium MedTech Pvt. Ltd., INSIGHTEC Ltd., Hironic Co.Ltd., Minerva Surgical Inc., Gynesonics Inc., Advanced Surgical Concepts PLLC, Hitachi Medical Corporation

What Are the Primary Growth Drivers in the Uterine Fibroid Embolization Device Market?

The surge in demand for less invasive surgical procedures is forecasted to significantly boost the uterine fibroid embolization device market’s growth. These surgeries denote methods that use small entry points or natural body orifices to treat various internal organs and structures, minimizing physical trauma inflicted on the patient. Uterine fibroid embolization devices, integral to these procedures, are specifically designed to reduce invasiveness, causing less damage to adjacent tissues. They also address the rising demand for less invasive healthcare procedures, resulting in better patient outcomes. For example, The Aesthetic Society, a US-based organization focused on plastic surgery and cosmetic medicine, reported in August 2023 that Americans spent over $11.8 billion on aesthetic procedures, a 2% increase from the prior year. Hence, the escalating demand for less invasive surgeries fuels the growth of the uterine fibroid embolization device market.

Uterine Fibroid Embolization Device Market Driver: Growing Elderly Population Spurs Uterine Fibroid Embolization Devices Market Expansion

 

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13551&type=smp

What Are the Leading Segments in the Global Uterine Fibroid Embolization Device Industry?

The uterine fibroid embolization device market covered in this report is segmented –

1) By Technology: Surgical Techniques, Laparoscopic Techniques, Ablation Techniques, Embolization Techniques

2) By Mode Of Treatment: Invasive Treatment, Minimally Invasive Treatment, Non-Invasive Treatment

3) By End User: Hospitals, Clinics, Ambulatory Surgical Center

Subsegments:

1) By Surgical Techniques: Open Surgery, Myomectomy

2) By Laparoscopic Techniques: Laparoscopic Myomectomy, Laparoscopic Hysterectomy

3) By Ablation Techniques: Radiofrequency Ablation, Microwave Ablation, Cryoablation

4) By Embolization Techniques: Transcatheter Arterial Embolization (TAE), Uterine Artery Embolization (UAE)

What Are the Key Market Trends in the Uterine Fibroid Embolization Device Industry?

Major industry players in the uterine fibroid embolization device market are escalating their game by creating cutting-edge products, such as the TruClear system. This innovative solution was initiated to meet the escalating demand for minimally invasive therapies for uterine fibroids and enhance the safety and effectiveness of uterine fibroid treatments. The TruClear system is a flexible catheter used as a mechanical hysteroscopic tissue removal instrument for addressing intrauterine abnormalities (IUA), and it is inserted into the uterus via the cervix. For instance, in November 2022, Medtronic Private Limited, an industry-leading medical equipment manufacturer based in India, introduced the innovative TruClear system. As a mechanical hysteroscopic tissue removal system, it provides a secure and potent solution for treating IUA. Furthermore, its compact size, flexibility, nitinol wire loop, continuous inflow and outflow, built-in suction, and high-definition imaging features contribute to the enhancement of precision and safety when conducting uterine fibroid treatments.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/uterine-fibroid-embolization-device-global-market-report

What Is the Regional Outlook for the Uterine Fibroid Embolization Device Market?

North America was the largest region in the uterine fibroid embolization device market in 2024. The regions covered in the uterine fibroid embolization device market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13551

This Report Delivers Insight On:

1. How big is the uterine fibroid embolization device market, and how is it changing globally?

2. Who are the major companies in the uterine fibroid embolization device market, and how are they performing?

3. What are the key opportunities and risks in the uterine fibroid embolization device market right now?

4. Which products or customer segments are growing the most in the uterine fibroid embolization device market?

5. What factors are helping or slowing down the growth of the uterine fibroid embolization device market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the uterine fibroid embolization device industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Has the Uterine Fibroid Embolization Device Market Growth Performance Trended Historically, And What Lies Ahead?

The market size for uterine fibroid embolization devices has shown robust growth in the past few years. It is projected to increase from $5.62 billion in 2024 to $5.93 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 5.6%. The substantial market growth in the prior period can be credited to the surge in the occurrence of uterine fibroids, the preference for non-invasive alternatives, initiatives to raise awareness and education, focus on the health of women, transition to outpatient procedures, and training programs for physicians.

The market for uterine fibroid embolization devices is anticipated to experience consistent expansion in the approaching years, culminating in a value of $7.04 billion by 2029, reflecting a compound annual growth rate (CAGR) of 4.4%. This projected growth can be linked to the rising public awareness about non-invasive treatments, the global proliferation of health care services, increased female health initiatives, integration with multi-disciplinary care, and outpatient service expansion. The period under forecast is likely to be defined by trends such as the heightened implementation of minimally invasive procedures, developments in embolic agents, customized treatment strategies, emphasis on outpatient ufe procedures, the incorporation of imaging technologies, and studies pertaining to bioresorbable embolic agents.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13551&type=smp

What Are the Primary Drivers Supporting the Market Growth of the Uterine Fibroid Embolization Device Market?

The surge in minimally invasive surgeries is predicted to bolster the uterine fibroid embolization device market. These type of surgeries involve the use of the natural body openings or small incisions to reach and treat the internal structures, tissues, or organs with the aim to reduce the trauma inflicted on the patient’s body. Uterine fibroid embolization devices are key instruments empowering these minimally invasive surgeries to efficiently cure uterine fibroids. Created with meticulous precision, these devices minimize invasiveness by employing small incisions and minimize disruption to nearby tissues. They help address the growing need for less invasive medical procedures, thus enhancing patient outcomes. For example, The Aesthetic Society, a US-based body dedicated to plastic surgery and cosmetic medicine, stated in August 2023 that aesthetic procedures worth more than $11.8 billion were undertaken by Americans, marking a rise of 2% from the preceding year. As such, the mounting demand for minimally invasive surgeries is fostering the expansion of the uterine fibroid embolization device market. The uterine fibroid embolization devices market is expected to be driven by a growing aging population. The term aging population refers to the ratio of individuals aged 65 and over within a population group. Uterine fibroid embolization devices assist in tackling symptomatic fibroids among the elderly, offering a less invasive solution to surgery, and mitigating symptoms such as excessive bleeding and pelvic discomfort. For example, the Switzerland-based intergovernmental body, World Health Organization, reported in October 2022 that the population segment aged 60 and above had soared to 1.4 billion in 2022. It is predicted that by 2050, the global population of individuals aged 60 and above will double to 2.1 billion. Hence, the swelling aging population is leading to the expansion of the uterine fibroid embolization devices market.

Which Primary Segments of the Uterine Fibroid Embolization Device Market Are Driving Growth and Industry Transformations?

The uterine fibroid embolization device market covered in this report is segmented –

1) By Technology: Surgical Techniques, Laparoscopic Techniques, Ablation Techniques, Embolization Techniques

2) By Mode Of Treatment: Invasive Treatment, Minimally Invasive Treatment, Non-Invasive Treatment

3) By End User: Hospitals, Clinics, Ambulatory Surgical Center

Subsegments:

1) By Surgical Techniques: Open Surgery, Myomectomy

2) By Laparoscopic Techniques: Laparoscopic Myomectomy, Laparoscopic Hysterectomy

3) By Ablation Techniques: Radiofrequency Ablation, Microwave Ablation, Cryoablation

4) By Embolization Techniques: Transcatheter Arterial Embolization (TAE), Uterine Artery Embolization (UAE)

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=13551&type=smp

Which Regions Are Key Players in the Growth of the Uterine Fibroid Embolization Device Market?

North America was the largest region in the uterine fibroid embolization device market in 2024. The regions covered in the uterine fibroid embolization device market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Most Significant Market Trends in the Uterine Fibroid Embolization Device Market?

In the uterine fibroid embolization device market, leading corporations such as Medtronic Private Limited are innovating and crafting products like the TruClear system. They aim to fulfil the increasing demand for less intrusive solutions for uterine fibroids. The TruClear technology enhances the security and effectiveness of uterine fibroid treatments. The system operates mechanically in its function as a hysteroscopic tissue remover for intrauterine abnormalities (IUA). This flexible catheter makes its way into the uterus via the cervix. In November 2022, the India-based industrial medical equipment manufacturer, Medtronic Private Limited, introduced the TruClear system. This system provides a reliable and efficient treatment for IUA. Furthermore, the compact catheter, equipped with a circulating nitinol wire loop, consistent inflow and outflow, incorporated suction, and high-definition imaging, has improved the accuracy and safety of treating uterine fibroids.

View the full report here:

https://www.thebusinessresearchcompany.com/report/uterine-fibroid-embolization-device-global-market-report

What Parameters Are Used to Define the Uterine Fibroid Embolization Device Market?

A uterine fibroid embolization device is a medical device that is used to treat noncancerous tumors using a minimally invasive process. Uterine fibroids are noncancerous growths of the uterus. This device restricts blood supply to uterine fibroids, causing them to shrink and eventually disappear.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13551

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Major Innovations Are Driving the Accelerated Growth of the Uterine Fibroid Embolization Device Market?

The uptick in demand for minimally invasive surgical procedures is predicted to boost the growth of the uterine fibroid embolization device market. Minimally invasive surgeries involve operating through small incisions or natural body orifices, facilitating a lesser degree of bodily trauma. The role of uterine fibroid embolization devices in these types of surgeries is crucial as they allow effective treatment of uterine fibroids with reduced invasiveness and minimal collateral impact on adjacent tissues. Consequently, these types of surgeries are gaining traction, contributing to improved patient outcomes. For instance, data from The Aesthetic Society (a US-based organization of plastic surgery and cosmetic medicine) in August 2023 documented that Americans spent over $11.8 billion on aesthetic procedures, marking a 2% increase from prior year records. Thus, the market for uterine fibroid embolization devices is benefiting from the rising demand for such surgeries. Rise in Aging Population Fuels Growth of Uterine Fibroid Embolization Device Market

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13551&type=smp

#What is the Projected CAGR for the Uterine Fibroid Embolization Device Market Size from 2025 to 2034?

In recent times, the market size for uterine fibroid embolization devices has seen robust growth. It is projected to grow from a value of $5.62 billion in 2024 to a worth of $5.93 billion in 2025, with a compound annual growth rate (CAGR) of 5.6%. Factors contributing to the growth during the historic period include an increasing occurrence of uterine fibroids, a preference for non-surgical alternatives, initiatives on awareness and education, a greater emphasis on women’s health, a transition towards outpatient procedures, and programs training physicians.

The market for uterine fibroid embolization devices is projected to experience consistent expansion in the forthcoming years, reaching a value of $7.04 billion in 2029 with a compound annual growth rate of 4.4%. The imminent growth within the forecast period can be associated with an uptick in the awareness about non-invasive therapies, worldwide growth of healthcare facilities, improvements in women’s health programs, collaboration with multi-specialty care, and the growth of outpatient services. The overall forecast period will be marked by key trends such as the rise in the usage of minimally invasive techniques, progression in embolic agents, customized treatment strategies, emphasis on outpatient ufe procedures, combination of imaging technologies, and research into bioresorbable embolic agents.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13551

What Are the Most Significant Market Trends Transforming theUterine Fibroid Embolization Device Market?

Leading firms in the uterine fibroid embolization device market like Medtronic Private Limited are creating ground-breaking products such as the TruClear system to cater to the rising demand for less invasive uterine fibroid treatments, and to enhance the safety and effectiveness of said treatments. The TruClear mechanism, a mechanical hysteroscopic tissue extraction system, addresses intrauterine irregularities (IUA). It’s a flexible catheter inserted into the uterus via the cervix. In November 2022, Medtronic, an industrial medical equipment manufacturer located in India, introduced this novel TruClear system. It offers a safe and effective solution for treating IUA, with its easy-to-use, flexible catheter built with a revolving nitinol wire loop, continuous inflow, and outflow, integrated suction, and advanced imaging capabilities. This greatly improves the accuracy and safety of the procedures used to treat uterine fibroids.

What Are the Top Market Players Propelling the Growth of theUterine Fibroid Embolization Device Industry?

Major companies operating in the uterine fibroid embolization device market report are Johnson and Johnson Pvt Ltd., Abbott Laboratories, Medtronic plc., Siemens Healthineers Ltd., Koninklijke Philips N.V., Stryker Corporation, Boston Scientific Corporation, GE HealthCare Technologies Inc., Olympus Corporation, Terumo Corporation, Smith and Nephew plc., Ethicon Inc., Hologic Inc., CooperSurgical Inc., Ferring B.V., Cook Medical Inc., Karl Storz GmbH, Merit Medical Systems, CONMED Corporation, Amsino International Inc., Lumenis Ltd., Richard Wolf GmbH, BTG International Ltd., Healthium MedTech Pvt. Ltd., INSIGHTEC Ltd., Hironic Co.Ltd., Minerva Surgical Inc., Gynesonics Inc., Advanced Surgical Concepts PLLC, Hitachi Medical Corporation

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/uterine-fibroid-embolization-device-global-market-report

Which Primary Segments of the Uterine Fibroid Embolization Device Market Are Driving Growth and Industry Transformations?

The uterine fibroid embolization device market covered in this report is segmented –

1) By Technology: Surgical Techniques, Laparoscopic Techniques, Ablation Techniques, Embolization Techniques

2) By Mode Of Treatment: Invasive Treatment, Minimally Invasive Treatment, Non-Invasive Treatment

3) By End User: Hospitals, Clinics, Ambulatory Surgical Center

Subsegments:

1) By Surgical Techniques: Open Surgery, Myomectomy

2) By Laparoscopic Techniques: Laparoscopic Myomectomy, Laparoscopic Hysterectomy

3) By Ablation Techniques: Radiofrequency Ablation, Microwave Ablation, Cryoablation

4) By Embolization Techniques: Transcatheter Arterial Embolization (TAE), Uterine Artery Embolization (UAE)

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=13551&type=smp

Which Regions Are Key Players in the Growth of the #What Major Innovations Are Driving the Accelerated Growth of the Uterine Fibroid Embolization Device Market?# Market?

North America was the largest region in the uterine fibroid embolization device market in 2024. The regions covered in the uterine fibroid embolization device market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Uterine Fibroid Embolization Device Market 2025, By The Business Research Company:

Magnetic Resonance Imaging Systems Devices And Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/magnetic-resonance-imaging-systems-devices-and-equipment-global-market-report

Immunochemistry Diagnostic Devices And Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/immunochemistry-diagnostic-devices-and-equipment-global-market-report

Lancing Devices And Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/lancing-devices-and-equipment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: